David Budd's guest appearances

David Budd

Share Talk LTD

David Smith

Ben Crawford

Andrew Scott

Adam Davidson

Richard Lee

James Campbell

Paul Johnson

Vinay Gupta

Tim Allen

David Price

Bob Smith

John Taylor

Craig Brown

Michael Foster

Alan Simpson

OwlTail

Share Talk caught up with Manchester-based company Genedrive PLC and spoke with David Budd, CEO about the company recent announcement with the development of two coronavirus test, one for central labs, hospital use and the other for community use. David Budd, Chief Executive Officer of genedrive plc, said: "The development teams at genedrive and at Cytiva have worked tirelessly over the past 2 months to develop our unique product that has the potential to streamline lab testing, improve quality, and ultimately allow more people to be tested. CE marking was achieved with performance studies and validations that will also support regulatory applications in other jurisdictions, such as Emergency Use Authorisation with the USA FDA and Emergency Use Assessment and Listing with the WHO. The temperature stable nature of the Genedrive® 96 SARS-CoV-2 kit means we have the potential to easily access these global markets, which are in urgent need of testing efficiency and volume."

Share Talk caught up with Manchester-based company Genedrive PLC and spoke with David Budd, CEO about the company recent announcement with the development of two coronavirus test, one for central labs, hospital use and the other for community use.  David Budd, Chief Executive Officer of genedrive plc, said: "The development teams at genedrive and at Cytiva have worked tirelessly over the past 2 months to develop our unique product that has the potential to streamline lab testing, improve quality, and ultimately allow more people to be tested. CE marking was achieved with performance studies and validations that will also support regulatory applications in other jurisdictions, such as Emergency Use Authorisation with the USA FDA and Emergency Use Assessment and Listing with the WHO. The temperature stable nature of the Genedrive® 96 SARS-CoV-2 kit means we have the potential to easily access these global markets, which are in urgent need of testing efficiency and volume."

David Budd, Chief Executive Officer of Genedrive PLC (GDR.L) 

We caught up with Manchester based company Genedrive PLC and spoke with David Budd about the company progress and what he has planned for the future.  Decentralising molecular diagnostics genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. We are passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by Global Health issues. Genedrive® development has been validated through a range of applications and external independent evaluations. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and the Asia Pacific region. genedrive plc has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and selected countries of the Asia Pacific region, and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India. The company also has an active development programme underway for Tuberculosis detection and drug resistance assessment. genedrive plc is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With an historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.

We caught up with Manchester based company Genedrive PLC and spoke with David Budd about the company progress and what he has planned for the future. Decentralising molecular diagnostics genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. We are passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by Global Health issues. Genedrive® development has been validated through a range of applications and external independent evaluations. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and the Asia Pacific region. genedrive plc has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and selected countries of the Asia Pacific region, and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India. The company also has an active development programme underway for Tuberculosis detection and drug resistance assessment. genedrive plc is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With an historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.

8: David Budd, CEO, Genedrive PLC (LON:GDR) 